Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen
Status:
Completed
Trial end date:
2014-12-15
Target enrollment:
Participant gender:
Summary
This is a single arm, single center, non-randomized, phase II trial of stage IIB/III TNBC.
Patients received neoadjuvant chemotherapy with cisplatin (50 mg/m2) in combination with
doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6
cycles. After surgery, adjuvant chemotherapy consisting of docetaxel (75 mg/m2) every 21 days
was further provided for 4 cycles. Primary outcome was pathological complete response in the
breast and axilla (pCR; ypT0ypN0). Secondary outcomes were safety, disease-free survival and
overall survival.